Spero Therapeutics has received approval from the US Food and Drug Administration (FDA) to begin a Phase III clinical trial of its investigational new drug (IND) application SPR994 for the treatment of complicated urinary tract infections (cUTI).

The approval has also allowed Spero to enrol patients for its ADAPT-PO trial in the US.

Spero Therapeutics CEO Ankit Mahadevia said: “With the FDA’s acceptance of our IND application for SPR994, we are excited to continue our Phase III initiation efforts, including opening clinical trial sites for enrolment in the US.”

ADAPT-PO includes a global, double-blind, double-dummy study design.

It aims to compare oral SPR994 with current standard of care, intravenous (IV) antibiotic ertapenem.

“We are excited to continue our Phase III initiation efforts, including opening clinical trial sites for enrolment in the US.”

Patients will be randomised in 1:1 ratio in each of the study arms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary objective will be the combined clinical and microbiological response with a 10% non-inferiority margin against IV ertapenem.

A lead-in cohort of 70 patients is also expected to be included in the trial to perform pharmacokinetics assessment for confirming the dose and exposure in the cUTI patient population.

Interim pharmacokinetic results from the trial’s lead-in cohort are expected to be available in the second half of this year.

Spero has already commenced initial activities of the ADAPT-PO trial and plans to open trial sites to enrol subjects in the first quarter of this year.

The company is also set to perform other clinical pharmacology studies simultaneously with the ADAPT-PO clinical trial.

These studies include a renal insufficiency study, a QT prolongation study, and a drug-drug interaction study.